Spun out of Celera Genomics Corporation, Virobay Inc is clinical-stage biopharmaceutical company utilizing their cysteine cathepsin platform for the development and commercialization of novel drugs. Focused on Cystene Cathepsin enzyme research for the potential treatment of Crohns Disease, other autoimmune diseases, fibrosis, and neSpun out of Celera Genomics Corporation, Virobay Inc is clinical-stage biopharmaceutical company utilizing their cysteine cathepsin platform for the development and commercialization of novel drugs. Focused on Cystene Cathepsin enzyme research for the potential treatment of Crohns Disease, other autoimmune diseases, fibrosis, and neuropathic pain, the firm's product candidates has a novel mechanism of action, addresses patient populations for which better therapies are still needed and represents a significant commercial opportunity. The firm is using biomarkers as potential companion diagnostics intended to allow optimization of dosing schedules and potentially to identify patient populations, facilitating effective and efficient trial design. The firm had attempted a $50M public offering in September 2014 but withdrew only a weeks later.
